Related by context. All words. (Click for frequent words.) 68 Adjuvant Treatment 66 Combination REOLYSIN R 65 STRIDE PD 65 Hormone Refractory Prostate Cancer 64 recurrent metastatic 64 registrational Phase 64 Neoadjuvant 64 BCIRG 64 relapsed MM 64 Shows Efficacy 64 evaluating tivozanib 64 Pertuzumab 64 Patients Receiving 64 Shows Promise Against 64 Temsirolimus 64 Refractory Angina 64 Prednisone Against Refractory 64 Sipuleucel T 64 assessing T DM1 63 Tumor Response 63 CYT# potent vascular disrupting 63 Hsp# Inhibitor 63 Achieves Primary Endpoint 63 Prolongs Survival 63 Tesmilifene 63 relapsing remitting MS RRMS 63 MAGE A3 ASCI 63 Drug Shows Promise 63 Cervical Dysplasia 63 mitoxantrone plus 63 Levels Linked 63 Pooled Analysis 63 Lung Cancer Drug 63 Randomized controlled 63 recurrent glioblastoma multiforme 63 follicular Non Hodgkin 62 Xelox 62 adjuvant cisplatin 62 Therapy Reduces 62 Desvenlafaxine Succinate 62 prospective multicentre 62 Bone Metastases 62 Improves Outcomes 62 LungAlert TM 62 Node Positive 62 Bayer HealthCare Onyx Pharmaceuticals 62 Zemplar Capsules 62 Randomized Phase II 62 Gastric Cancer 62 Subgroup analysis 62 NSABP B 62 number NCT# ClinicalTrials.gov 62 Tykerb lapatinib 62 Deforolimus 62 Improves Survival 62 Teva Provides Update 62 Edge STudy 62 Breast Density 62 Breast Cancer Recurrence 62 HER2 Positive 62 Shows Promising 62 NSABP C 62 Intervention Effectiveness 62 ENESTnd 62 LHRH receptor positive 61 Renal Cell Carcinoma 61 Fulvestrant 61 demonstrated antitumor activity 61 Vildagliptin 61 deCODE ProstateCancer TM 61 multicenter randomized controlled 61 Safinamide 61 mg/m2 cohort 61 evaluating mipomersen 61 hormone receptor negative 61 Cholesterol Levels SPARCL 61 anastrazole 61 Treatment Shows Promise 61 PLX STROKE targeting 61 Demonstrates Positive 61 Cardiotoxicity 61 CUSTOM III 61 receptor tyrosine kinase inhibitor 61 Tibolone 61 Glucosamine Chondroitin Arthritis 61 Arranon 61 CYP#D# inhibitor 61 Carotid Revascularization Endarterectomy vs. 61 R lenalidomide 61 Appears Safe 61 hormonally sensitive 61 Heterozygous Familial Hypercholesterolemia 61 Toremifene 61 Vertex hepatitis C 61 Completes Patient Enrollment 61 nonmetastatic 61 prospectively stratified 61 paclitaxel cisplatin 61 Randomized Study 61 Degarelix 61 Drug Combo 61 Dasatinib 61 Femara letrozole 61 beta carotene supplementation 61 Initiates Enrollment 61 Efficacy Trial 61 Xeloda ® 61 Demonstrates Efficacy 61 Cholesterol Lowering Drug 61 Pivotal Clinical Trial 61 Therapeutic Efficacy 61 evaluating satraplatin plus 61 Initiates Phase III 61 Randomized Phase 61 CALERIE 61 Phase III ADT 61 Oral Fingolimod 61 Pivotal Phase III 60 Uterine Cancer 60 Mg Usa 60 Microalbuminuria 60 Meets Primary Endpoint 60 Randomized Double blind 60 Hepatotoxicity 60 CLARITY study 60 midstage clinical 60 Genes Identified 60 Preclinical Models 60 Treatment Reduces 60 Severe Sepsis 60 ZACTIMA 60 randomized Phase IIb 60 Reduce Cardiovascular 60 Sentinel Lymph Node Biopsy 60 Protease Inhibitors 60 Immunomedics Announces 60 Cardiac Resynchronization 60 Onyx Pharmaceuticals Announces 60 Adjuvant chemotherapy 60 Nicotine Vaccine 60 opioid naive 60 ACCORD Lipid 60 Exemestane 60 cisplatin gemcitabine 60 bladder ovarian 60 zoledronic acid Reclast 60 Relapsed Multiple Myeloma 60 galiximab 60 Anthracycline 60 RIO Lipids 60 FUSILEV enhances 60 Naive Patients 60 SPRYCEL ® 60 Combo Therapy 60 Interferon Beta 60 Polyp Prevention Trial 60 Paclitaxel Carboplatin 60 Predict Response 60 multicenter multinational 60 Phase IIb III 60 Phase IIIb clinical 60 Randomized Double Blind 60 hematological parameters 60 Vaccine Shows Promise 60 OncoVex 60 acute mania 60 Aeolus Pharmaceuticals Announces 60 Patients Treated With 60 Colorectal Cancers 60 pertuzumab 60 Peginterferon alfa 2b 60 ICON7 60 ovarian endometrial 60 acyclovir Lauriad R 60 Solid Tumor 60 Demonstrate Significant 60 Phase IIA 60 SUTENT ® 60 Novel Inhibitor 60 Anti Tumor 60 RE MODEL 60 Adjuvant Chemotherapy 60 Slow Progression 60 somatostatin analog 60 Pre Exposure Prophylaxis 60 Randomised 60 Preclinical Study 60 Reduces Mortality 60 Antisoma AS# 60 Subgroup Analysis 60 epoetin alpha 60 tramiprosate Alzhemed TM 60 Breast Cancer Treatment 60 Lipid Lowering 60 finasteride Proscar 60 cisplatin resistant 60 AVAiL 60 Coronary Artery Calcium 59 Vicriviroc 59 Advanced Melanoma 59 Phase 2b Clinical Trial 59 Enzastaurin 59 Bosutinib 59 invasive lobular carcinoma 59 Plaquenil 59 PF # [002] 59 Proves Effective 59 Tyrosine Kinase Inhibitor 59 Aflibercept 59 Newly Diagnosed Multiple Myeloma 59 patients receiving myelosuppressive 59 ToGA 59 HER2 Positive Breast Cancer 59 refractory metastatic 59 prednisone prednisolone plus 59 interstitial brachytherapy 59 Demonstrates Potential 59 visceral metastases 59 Motesanib 59 Prostate AdenoCarcinoma Treatment 59 SIMPADICO 59 LAB CGRP 59 Hormone Replacement 59 Lowers Risk 59 Ovarian Cancer Patients 59 trastuzumab DM1 59 Trastuzumab DM1 59 Main Outcome Measure 59 Adjuvant Therapy 59 IMPACT DCM 59 taxane chemotherapy administered 59 Shows Statistically Significant 59 landmark ATHENA 59 Ovarian Cancers 59 progressive metastatic prostate 59 OvaRex MAb 59 Endometrial 59 Menopausal hormone therapy 59 HIV HCV coinfected 59 Demonstrates Significant 59 Genes Linked 59 Drug Fails 59 Ceplene/IL-2 59 Confirms Efficacy 59 BRIM3 59 ductal carcinomas 59 HER2 amplified 59 Topoisomerase II 59 ACTIVE W 59 Intravitreal 59 nonnucleoside reverse transcriptase inhibitors 59 Randomized trials 59 Coronary Artery Bypass Graft 59 BR.# 59 Helps Smokers Quit 59 pioglitazone hydrochloride 59 tarenflurbil 59 estramustine 59 ABCSG 59 Bezielle 59 Multicenter Randomized 59 Lung Cancer Survival 59 Follicular Lymphoma 59 pancreatic prostate 59 Phase III Clinical Trial 59 PROSTVAC VF 59 Anticancer Drug 59 metastatic HER2 negative 59 metastatic colorectal 59 recurrent malignant glioma 59 CALGB 59 Boosts Survival 59 Telik Announces 59 Test Detects 59 Breast Cancer Cells 59 Fixed Dose 59 Vaccine Protects Against 59 novel VDA molecule 59 selenium supplementation 59 PRESEPT 59 lymphomas leukemias 59 Relapsing Multiple Sclerosis 59 Postmenopausal hormone therapy 59 androgen suppression 59 Heart Failure Patients 59 Soft Tissue Sarcoma 59 Decompensated Heart Failure 59 Prostate Cancer Prevention 59 FDA Okays 59 FDA Approves Generic 59 PLX MS 59 adjuvant colon cancer 59 Pemetrexed 59 Trandolapril 59 Teriflunomide 59 endometrial carcinoma 59 TransVax 59 Risk Stratification 59 Fingolimod 59 Eases Pain 59 Advaxis Phase 59 Prevent Breast Cancer 59 Bazedoxifene 59 Multiple Ascending Dose 59 Fibroblast 59 drug NP2 Enkephalin 59 Vaccine Prevents 59 Silodosin 59 Successfully Completes Phase 59 Phase III AFFIRM 59 azilsartan medoxomil 59 WHEL 59 Vidaza ® 59 IIa Clinical Trial 59 PENNVAX ™ B 59 Phase Ib IIa 59 Epithelial Cell 59 Phase 1a clinical 59 CAMMS# 59 Unstable Angina 59 Muraglitazar 59 GOUT 59 Ovarian Cancer Screening 59 Active Ulcerative Colitis 59 Antitumor 59 neratinib 58 benign prostatic hyperplasia enlarged 58 Reduces Pain 58 hormone receptor status 58 Malignant Melanoma 58 Launches Generic Version 58 Prospective Multicenter 58 Initiate Phase III 58 cediranib 58 Etanercept 58 Cholesterol Drug 58 Nilotinib 58 pain palliation 58 pharmacodynamic effects 58 Roche Herceptin 58 #mg ATC 58 Randomized Clinical Trials 58 FDA Approves Drug 58 endocrine responsive 58 Inhaled nitric oxide 58 Antitumor Activity 58 Long Term Efficacy 58 ® lenalidomide 58 Clinical Validation 58 VIVUS Announces 58 humanised antibody designed 58 Aggressive Reduction 58 visit http:/www.clinicaltrials.gov/ 58 Antiarrhythmic 58 metastatic malignant 58 zoledronate 58 phase Ib 58 Survival Benefit 58 forodesine 58 HORIZONS AMI 58 HCV RESPOND 2 58 Nesiritide 58 HCV SPRINT 58 CIPN 58 Phase III multicenter 58 ixabepilone 58 Sprycel dasatinib 58 Screening Trial DMIST 58 Glioma 58 Bucindolol 58 Showed Significant 58 Acute Liver Failure 58 Fracture Intervention Trial 58 HER2 overexpression 58 PSMA ADC 58 confirmatory clinical 58 Stage IIB 58 RECORD1 58 Tanespimycin 58 PhG alpha 1 58 Val HeFT 58 Glioblastoma Multiforme 58 doxorubicin cyclophosphamide 58 INSPIRE Trial Phase III 58 Study Evaluating 58 thalidomide Thalomid 58 BRCA deficient 58 multicenter prospective 58 noninvasive outpatient 58 Stomach Cancer 58 Rheumatoid Arthritis Drug 58 CARE HF 58 multicenter placebo controlled 58 Bevacizumab Avastin 58 gamma secretase inhibitor 58 Phase 1b clinical trials 58 Celebrex celecoxib 58 AVERROES 58 ACTEMRA TM 58 humanized therapeutic 58 Hepatocellular Carcinoma HCC 58 AA Amyloidosis 58 Pegylated Interferon 58 B Cell Lymphoma 58 Decitabine 58 Node Negative 58 postoperative chemotherapy 58 dose escalation phase 58 Endometrial Cancer 58 Metastatic Prostate Cancer 58 evaluating T DM1 58 Diabetic Foot Ulcer 58 postmenopausal hormones 58 BEXXAR Therapeutic Regimen 58 Stent Thrombosis 58 refractory colorectal cancer 58 Liraglutide Effect 58 Estrogen receptor positive 58 Multicenter Phase 58 Hemodialysis Patients 58 Interferon beta 1b 58 Hepatocellular 58 multicenter Phase II 58 Therapy Shows Promise 58 pregabalin Lyrica 58 lenalidomide Revlimid 58 Recurrent Breast Cancer 58 deCODE BreastCancer 58 Natalizumab 58 evaluating satraplatin 58 Aurora Kinase 58 LUMINATE 58 Clinical Outcomes Utilizing Revascularization 58 Psoriasis Drug 58 Confirmatory 58 Diabetic Neuropathy 58 Delcath Phase III 58 Chemoradiation 58 Olaparib 58 Genes Predict 58 Fondaparinux 58 Cancer Incidence Mortality 58 Raloxifene Evaluation MORE 58 HYVET 58 Transdermal Patch 58 CHARM Added 58 peritoneal cancer 58 Investigational Drug 58 Known hypersensitivity 58 deCODE AF TM 58 stage IIIb IV 58 Adenoma Prevention 58 Glycopyrrolate 58 Amgen denosumab 58 Lung Cancer Patients 58 Intervention Trial GAIT 58 Immunotherapeutic 58 Darinaparsin 58 Vidaza azacitidine 58 R Bortezomib 58 #-# Full Text 58 alvespimycin 58 Phase III Psoriasis 58 Reduced Risk 58 Investigational Treatment 58 protein tyrosine phosphatase 1B 58 dalteparin 57 medroxyprogesterone acetate 57 GW# [003] 57 deep venous thromboses 57 Targeted Therapy 57 Therapy Improves 57 CURRENT OASIS 7 57 OVATURE 57 evaluating Actimmune 57 Diamyd r 57 PRESEPT study 57 kidney urologic 57 Initiate Phase 57 Dose Escalation 57 interferon beta therapy 57 #rd Annual CTRC 57 aromatase inhibitors AIs 57 Folfox 57 Could Predict 57 Prolongs Life 57 potent suppressor 57 Study Shows Significant 57 Transplant Rejection 57 Pivotal Phase 57 Mg Uk 57 Demonstrates Potent 57 Lipitor #mg 57 Initiated Phase 57 Biomarker Study 57 Relapsing Remitting Multiple Sclerosis 57 AVADO 57 Kinoid 57 Detect Lung Cancer 57 Cerebril TM 57 Phase Ib clinical 57 evaluating Prochymal 57 ASSERT 57 Prostate Cancer Vaccine 57 Celecoxib 57 EGS# 57 intravascular hemolysis 57 Genetic Markers 57 Lung Cancer Vaccine 57 Investigational Agent 57 Carotid Stenting 57 SORT OUT III 57 BioSante Pharmaceuticals Reports 57 pivotal bioequivalence 57 Trial Evaluating 57 approved incretin mimetic 57 ISEL 57 HDL Selective Delipidation 57 pravastatin Pravachol 57 Adjuvant Breast Cancer 57 Crizotinib 57 brivanib 57 Clinical Outcome 57 Leukemias 57 HMG CoA reductase inhibitors 57 ASCO GU 57 multicenter randomized clinical 57 Phase #b/#a clinical 57 Lilly Alimta 57 leukemia multiple myeloma 57 Estrogen Receptor 57 cause mesothelioma asbestosis 57 HER2 positive cancers 57 Aliskiren 57 NMIBC 57 AVN# Phase 57 Phase III Clinical Trials 57 CHAMPION PCI 57 Dendreon Provenge 57 Statistically Significant 57 GRNOPC1 contains 57 malignant ascites 57 budesonide foam 57 neoadjuvant treatment 57 drug figitumumab 57 CaPSURE 57 Localized Prostate Cancer 57 Daptomycin 57 5alpha reductase 57 motesanib diphosphate 57 dasatinib Sprycel 57 Aggressive Prostate Cancer 57 Intervention Effectiveness CATIE 57 ALSYMPCA 57 plus prednisone prednisolone 57 selective modulator 57 Ellence 57 underwent surgical resection 57 Brentuximab Vedotin SGN 57 Testosterone Patch 57 antiretroviral naïve 57 include ColorectAlert TM 57 Gene Linked 57 Prostate Lung Colorectal 57 Multicenter 57 docetaxel cisplatin 57 Statin Drugs 57 de novo kidney transplant 57 Recurrent Glioblastoma 57 Protein Linked 57 DVT prophylaxis cholesterol 57 Renal Cancer 57 hormone refractory metastatic prostate 57 Ophena TM 57 Oncotype 57 NCT# ClinicalTrials.gov 57 BRIM2 57 Pharmacogenetic 57 BRAF V#E mutation 57 PARP Inhibitor 57 riociguat 57 Thyroid Function 57 mertansine 57 dose escalation clinical 57 Clinical Trial Data 57 Phase Ib II 57 Allogeneic 57 randomized blinded 57 Atomoxetine 57 fosbretabulin 57 Gene Mutations 57 Prevent Stroke 57 RhuDex R 57 Genentech Provides Update 57 papillary renal cell carcinoma 57 Myocardial Perfusion 57 Study Demonstrates 57 COSTAR II 57 Adenomas 57 Teriparatide 57 Hormone Receptor Positive 57 immunomodulatory agents 57 See CLINICAL PHARMACOLOGY 57 Zarnestra 57 midstage trials 57 lenalidomide Revlimid R 57 Trabectedin 57 Catheter Associated 57 DEB# 57 Interferon beta 57 impaired insulin secretion 57 Motexafin Gadolinium 57 CIMZIA R 57 Immunosuppressant 57 placebo controlled clinical 57 concurrent ITP 57 metastatic renal 57 accumulate preferentially 57 novel therapeutic antibodies 57 Antiangiogenic 57 pegylated liposomal doxorubicin 57 RIO Diabetes 57 noscapine 57 Rheumatoid Arthritis Patients 57 pancreatic lung 57 REMINYL ® 57 Pegylated Liposomal Doxorubicin 57 Wyeth Progenics 57 VNP#M 57 ORAL Solo 57 Viral load 57 ® bortezomib 57 imexon 57 UPLYSO 57 Huggins Cams Time 57 YONDELIS 57 oral FTY# 57 5 fluorouracil leucovorin 57 Panzem R NCD 57 Orally Active 57 Osteoporosis Drug 57 TNFerade TM 57 Randomized Phase III 57 Skin Lesions 57 recombinant PSMA vaccine 57 R# #mg BID 57 oral rivaroxaban 57 Hypertrophy 57 ZOLINZA 57 CAPRIE 57 Spine Patient Outcomes 57 Analytical Tool 57 AOD# [002] 57 opioid naïve 57 Epirubicin 57 Effectively Treats 57 Neuvenge 57 bortezomib Velcade 57 Randomized Evaluation 57 Acute myelogenous leukemia 57 endometrial hyperplasia 57 SNT-MC#/idebenone 57 Initiates Phase II 57 Multicenter AIDS 57 CCR5 receptor antagonist 57 Breast Tumor 57 ACOMPLIA R 57 Alpha Tocopherol Beta Carotene 57 HER2 expression 57 Strongly Linked 57 BRCA1 BRCA2 57 Anticonvulsant 57 receiving XGEVA 57 Combination antiretroviral therapy 57 II Clinical Trial 57 Male Contraceptive 57 antihormonal 57 Prostatic 57 Oral contraceptive 57 KRN# 57 MADIT II 57 Initiate Phase II 57 prospective observational studies 57 Homeostasis 56 Invasive Breast Cancer 56 Fewer Side Effects 56 develop HBV reactivation 56 TASKi3 56 Myocardial Perfusion Imaging 56 Transplant Patients 56 resectable pancreatic cancer 56 CALGB # [001] 56 Kinase Inhibitor 56 headache nasopharyngitis 56 Cites Positive 56 Brain Metastases 56 inhibits blood clotting 56 Intravenous immunoglobulin 56 microtubule inhibitor 56 gemcitabine carboplatin 56 Pivotal Study 56 ARBITER 6 56 Targretin capsules 56 Vectibix panitumumab 56 neurologic progression 56 Gastrointestinal Stromal Tumors 56 Fabry Disease 56 Tipranavir 56 Fludara ® 56 Phase III Trial 56 nulliparous women 56 Blood Thinner 56 pharmacogenomic translational research 56 Ixempra 56 Bayer Nexavar 56 EXPLORE Xa 56 CIN2 + 56 chromium supplementation 56 oral clodronate 56 castration resistant hormone refractory 56 DASISION 56 Hydroxyurea 56 chemosensitizer 56 Li Fraumeni 56 Artificial pancreas 56 Febuxostat 56 Prestara 56 Aplidin 56 Tuberculosis Vaccine 56 Pharmacodynamic 56 Dose Response 56 Ischemic Stroke 56 HCV Protease Inhibitor 56 prospective nonrandomized 56 Dose Finding 56 Inflammatory Markers 56 Squamous Cell 56 Ragweed Allergy 56 Recurrent Prostate Cancer 56 Lupus Drug 56 Artery Disease 56 Clinical Trial Results 56 quadrivalent HPV vaccine 56 ERalpha 56 Temodar ® 56 metastatic pancreatic 56 Treating Chronic 56 Colorectal Screening 56 CALGB # [002] 56 Certolizumab pegol 56 morphometric vertebral fractures 56 trastuzumab Herceptin ® 56 transrectal ultrasound guided 56 Nipent R 56 CATIE AD 56 EchoCRT 56 LymphoStat B belimumab 56 skeletal metastases 56 BRCA2 mutation carriers 56 BRAF mutated 56 INTEGRILIN R eptifibatide Injection 56 Platelet Inhibition 56 Associated Diarrhea 56 MGd 56 vaccine Stimuvax 56 Hormone Receptor 56 breast endometrial 56 Capsules CII 56 Rotavirus Vaccine 56 Improve Survival 56 Pharmacokinetic parameters 56 Picoplatin Efficacy After 56 Sanofi Acomplia 56 Resistant Hypertension 56 antiangiogenic therapy 56 gefitinib Iressa 56 Sangamo BioSciences Announces 56 Multicenter Automatic Defibrillator Implantation 56 paclitaxel poliglumex 56 triggers apoptosis programmed 56 Double Blind Placebo 56 Lymphocytic 56 Sleep Disturbances 56 fusion enhancers 56 alkylating agent 56 NO# [002] 56 NeuroVax 56 motesanib 56 olaparib 56 Diabetes ACCORD 56 PYY #-# 56 Disease Progression 56 Prostate Cancer Patients 56 #F FDG PET 56 Benign Prostatic Hyperplasia 56 pretreatment serum 56 Liposomal Grb 2 56 R abatacept 56 Chronic Lymphocytic Leukemia 56 samalizumab 56 Fluorouracil 56 Anal Cancer 56 colorectal adenoma 56 Cinquil 56 HIV coinfected 56 urothelial cancer 56 Treatment Naive Patients 56 oral deforolimus 56 Novel Therapeutic 56 Radical Prostatectomy 56 Gemzar ® 56 B vitamin supplementation 56 HORIZONS AMI trial 56 Elocalcitol 56 Demonstrates Sustained 56 Omacetaxine 56 Romidepsin 56 Flu Cy 56 velafermin 56 postmenopausal estrogen 56 Digital Mammographic Imaging 56 Outpatient Setting 56 ENDEAVOR III 56 Schizophrenia Treatment 56 smoldering multiple myeloma 56 5 Fluorouracil 56 Acute Heart Failure 56 Drug Candidate 56 CYP#A# CYP#D# 56 anti arrhythmic drug 56 Colorectal Adenomas 56 Antihypertensive 56 FOLFOX6 chemotherapy regimen 56 SYMMETRY trial 56 treatment naive genotype 56 resistant hormone refractory 56 Anticancer Drugs 56 chronic idiopathic thrombocytopenic purpura 56 sunitinib Sutent 56 Imetelstat 56 superficial bladder cancer 56 randomized multicenter trial 56 PANVAC VF 56 nucleotide analogue 56 Hormone Therapy 56 orally inhaled migraine 56 OvaRex 56 Rheos System 56 Mycophenolate Mofetil 56 Proellex TM 56 OMP #R# 56 ASTEROID 56 Data Suggest 56 biliary tract cancer 56 recurrent epithelial ovarian 56 phase IIb trial 56 concurrent chemoradiation 56 Obesity Linked 56 Study Shows Benefits 56 R sorafenib tablets 56 Improved Survival 56 sargramostim 56 trastuzumab Herceptin R 56 HDAC Inhibitor 56 circulating endothelial cells 56 metastatic bladder 56 Angiotensin Converting Enzyme 56 BRAF mutant 56 SPIRIT FIRST 56 Sorafenib HCC Assessment 56 Study Casts Doubt 56 indolent follicular non 56 Anti Tumor Activity 56 adefovir dipivoxil 56 mGluR2 NAM 56 Placebo Controlled Trial 56 Antiplatelet 56 treat secondary hyperparathyroidism 56 trials RCTs 56 recurrent glioma 56 locoregional recurrence 56 Lymph node 56 taxane refractory 56 salpingo oophorectomy 56 Gemzar gemcitabine 56 Luveris 56 Femring ® 56 Scandinavian Simvastatin Survival 56 subcutaneous methylnaltrexone 56 TransVax ™ 56 Bioequivalence 56 Arthritis Drugs 56 Cimzia TM 56 Venous Thromboembolism 56 class mGluR5 inhibitor 56 Velcade bortezomib 56 lexidronam injection 56 smoldering myeloma 56 Irinotecan 56 hypercholesterolemic patients 56 Companion Diagnostic 56 lung pancreatic 56 Non inferiority 56 Fludarabine 56 venlafaxine XR 56 Papillary 56 Riluzole 56 Forodesine HCl 56 Hormonal Contraceptives 56 prospective observational 56 aurora kinase 56 Randomized Clinical Trial 56 lumiliximab 56 bacillus Calmette Guerin BCG 56 relapsed ALL 56 Genes Associated 56 Combination Treatment 56 Grouped Hockey 56 Vaxfectin formulated 56 ORACLE MS 56 3 registrational trial 56 AIR CF1 56 MVA MUC1 IL2 56 Pharmacologic 56 EndoTAGTM 1 56 Initiates Clinical 56 trastuzumab emtansine T DM1 56 Vincristine 56 PRIMO CABG2 56 RNAi Therapeutic 56 glatiramer 56 solid tumors ZYBRESTAT 56 Ziprasidone 56 Ovary removal 56 Capesaris 56 Epilepsy Drug 56 vinorelbine tartrate 56 adalimumab Humira 56 ThermoDox ® clinical 56 OMP #M# 56 Anti VEGF 56 Septic Shock 56 metastatic colorectal carcinoma 56 Lung Cancer Risk 56 ENABLE Phase 2 56 allogeneic HSCT 56 recurrent glioblastoma multiforme GBM 56 WHIMS 56 T1c 56 Trial Halted 56 Prostate specific antigen 56 multicentre randomized controlled 56 Empatic ™ 56 clomipramine 56 recurrent ovarian cancer 56 keloid scarring 56 hormone therapy estrogen 56 CINQUIL 56 adenoma recurrence 56 Tacrolimus 56 RhuDex 56 Non Melanoma Skin 56 Novo TTF 56 canakinumab 55 AML MDS 55 GENASIS 55 JAK Inhibitor 55 Cervical Cancer Screening 55 Adrenomyeloneuropathy AMN 55 Factor VIIa 55 Randomized Controlled 55 EVEREST II 55 Left Ventricular Dysfunction 55 BARACLUDE R 55 Placebo controlled 55 paricalcitol 55 randomized crossover 55 ovarian pancreatic 55 Acute Pancreatitis 55 dirucotide MBP# 55 Levoleucovorin 55 APEX AMI 55 Gynecologic Oncology Group 55 Granulocyte Colony Stimulating Factor 55 Phase 2a Trial 55 Anacetrapib 55 meta analysis pooling 55 Breast Cancers 55 phase IIIb 55 Lamotrigine 55 ACOSOG Z# 55 ATACAND 55 Triapine R 55 Metastatic Renal Cell Carcinoma 55 BRAF inhibitor 55 PRoFESS 55 Premenopausal 55 K ras mutations 55 Glatiramer acetate